Comparison of Cryotherapy and Peeling Agent in the Treatment of Common Warts
NCT ID: NCT05712811
Last Updated: 2023-02-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2022-06-01
2022-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study Design: Randomized Control Trial. Place And Duration of Study: Department of Dermatology, CMH Abbottabad from Jun 2022 to Nov, 2022.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparative Study Between Treatment With Cryotherapy Alone Versus Cryotherapy Plus Salicylic Acid Dressing for Planter Warts
NCT05588999
Efficacy of Cryotherapy Combined With Intralesional Tuberculin PPD Versus Intralesional Tuberculin PPD in Treatment of Multiple Common Warts
NCT04288817
Comparison of Topical 5%Potassium Hydroxide vs Liquid Nitrogen in the Treatment of Plane Warts
NCT05895071
Comparisom of Liquid Nitrogen and Vitamin D3 in The Treatment of Cutaneous Warts
NCT05739786
Comparison of Effectiveness of Topical Retinoids Versus Liquid Nitrogen in Treatment of Plantar Warts(Viral Infection)
NCT07016360
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A cryotherapy
Cryotherapy Group A had their warts treated once every two weeks for a total of twelve weeks, with liquid nitrogen using cryoget method for 10 to 15 seconds on each lesion (depending on size, until a narrow white rim of around 1 mm developed around it).
CRYOTHERAPY
Group A had their warts treated once every two weeks for a total of twelve weeks, with liquid nitrogen using cryoget method for 10 to 15 seconds on each lesion (depending on size, until a narrow white rim of around 1 mm developed around it).
Group B Topical TCA 90%
Topical TCA 90 % Warts in Group B were treated with liquid TCA 90% by an applicator every two weeks for a total of twelve weeks. After 20 minutes, patients were instructed to remove the solution by washing their warts with water or regular saline
Tricholoracetic acid
Group B were treated with liquid TCA 90% by an applicator every two weeks for a total of twelve weeks. After 20 minutes, patients were instructed to remove the solution by washing their warts with water or regular saline.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CRYOTHERAPY
Group A had their warts treated once every two weeks for a total of twelve weeks, with liquid nitrogen using cryoget method for 10 to 15 seconds on each lesion (depending on size, until a narrow white rim of around 1 mm developed around it).
Tricholoracetic acid
Group B were treated with liquid TCA 90% by an applicator every two weeks for a total of twelve weeks. After 20 minutes, patients were instructed to remove the solution by washing their warts with water or regular saline.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* genital warts
* cardiac, hepatic and renal disease
* hypercholesterolemia
* hypersensitivity reactions
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Combined Military Hospital Abbottabad
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr kiran gul
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cmh abbottabad
Abbottābād, Kpk, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CMHAbbottabad
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.